Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Results of neuroimaging for nonglaucomatous visual field defect
Author Affiliations & Notes
  • Na Eun Kim
    Severance Hospital, Seodaemun-gu, Seoul, Korea (the Republic of)
    Ophthalmology, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea (the Republic of)
  • Jihei Sara Lee
    Severance Hospital, Seodaemun-gu, Seoul, Korea (the Republic of)
    Ophthalmology, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea (the Republic of)
  • Chan Yun Kim
    Severance Hospital, Seodaemun-gu, Seoul, Korea (the Republic of)
    Ophthalmology, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea (the Republic of)
  • Hyoung Won Bae
    Severance Hospital, Seodaemun-gu, Seoul, Korea (the Republic of)
    Ophthalmology, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Na Eun Kim None; Jihei Lee None; Chan Yun Kim None; Hyoung Won Bae None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 5569. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Na Eun Kim, Jihei Sara Lee, Chan Yun Kim, Hyoung Won Bae; Results of neuroimaging for nonglaucomatous visual field defect. Invest. Ophthalmol. Vis. Sci. 2024;65(7):5569.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Guidelines about neuroimaging for patients with nonglaucomatous visual field defect (VFD) are sparse. We performed a retrospective, cross-sectional study to analyze the clinical presentations and neuroimaging findings of patients with nonglaucomatous VFD.

Methods : We included patients who underwent brain magnetic resonance imaging (MRI) for differential diagnosis of their nonglaucomatous VFD between 2013 and 2022. Patients with neurologic symptoms other than decreased visual acuity, those who have history of brain lesion, or those with systemic medication known to cause optic neuropathy were excluded. Demographic and ophthalmic characteristics were analyzed. The reasons for conducting brain MRI were classified into three: (1) VFD respecting vertical meridian, (2) VFD inconsistent with IOP or structural change, and (3) VFD with fast progression (aggravation of mean deviation over 1.5 dB per year). Logistic regression was conducted to identify independent risk factors for significant lesion responsible for nonglaucomatous VFD.

Results : A total of 159 patients (258 eyes) had undergone brain MRI, and 95 patients (169 eyes) had been diagnosed with open-angle glaucoma for at least one eye. For the pattern of VFD, arcuate VFD was the most common (36.9%) but the frequency of VFD pattern showed a significant difference depending on the glaucoma history (p=0.007). 29 patients (42 eyes) showed significant finding and intracranial tumor was the most common finding (9 patients), followed by cerebrovascular accident (6 patients). Presence of peripapillary atropy was associated with a 65% reduction in relative risk of significant finding in brain MRI (odds ratio [OR] 0.353, 95% confidence interval [CI] 0.136-0.919, p=0.033). Older age (OR 1.049, 95% CI 1.018-1.081, p=0.002), presence of visual acuity symptoms (OR 5.79, 95% CI 2.361-14.195, p<0.001), presence of incomplete homonymous hemianopsia (OR 15.167, 95% CI 3.096-74.30, p=0.001), and reason for taking brain MRI, VFD with fast progression, (OR 4.385, 95% CI 1.266-15.189, p=0.02) were analyzed to be independent risk factors for significant finding in brain MRI.

Conclusions : VFD with nongluacomatous pattern or progression may indicate lesion along visual pathway. For nonglaucomatous VFD, neuroimaging is recommended for patients who are older or with decreased visual acuity. It is also recommended for fast progression or incomplete homonymous hemianopsia.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×